^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Undisclosed Cbl-b inhibitor

i
Other names: Undisclosed Cbl-b inhibitor
Associations
Trials
Company:
Simcere, Sparkle Therap
Drug class:
CBLB expression inhibitor
Related drugs:
Associations
Trials
over1year
Identification of the selective CBL-b inhibitors which effectively prevent T cells from exhaustion and demonstrate synergistic anti-tumor activity in combination with an anti-PD1 antibody (AACR 2023)
In conclusion, our selective Cbl-b inhibitors demonstrated robust immune activation and anti-tumor activity in vitro and in vivo and showed synergistic activities with immune checkpoint inhibitors, such as anti-PD(L)1. Currently, one of our leading molecules is in IND enabling studies.
Combination therapy
|
IL2 (Interleukin 2) • VAV1 (Vav Guanine Nucleotide Exchange Factor 1)
|
Undisclosed Cbl-b inhibitor
over1year
Small molecule inhibitor of ubiquitin ligase CBL-B enhanced anti-tumor response of CAR-T and CAR-NK cell therapies (AACR 2023)
preclinical data provided evidence of CBL-B inhibitors to enhance key parameters associated with T/NK cell activation and reduce susceptibility to immune suppression. Our results suggest the combination strategy of cell therapy and immune regulating small/large molecule therapy might achieve better anti-tumor efficacy in both hematological and solid tumors.
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • TGFB1 (Transforming Growth Factor Beta 1) • IL15 (Interleukin 15) • NKG2D (killer cell lectin like receptor K1)
|
Undisclosed Cbl-b inhibitor